Evidence map›Paper›PMID 36051888›Full record

ArticleMultidisciplinary respiratory medicine2022

Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials.

Peter Kardos, Walter Lehmacher, Andrea Zimmermann, Juliette Brandes-Schramm, Petra Funk, Heinrich Matthys, Wolfgang Kamin

Open access · goldAbstract read
In one paragraph

Article in Multidisciplinary respiratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Peter KardosGroup Practice and Centre Allergy, Respiratory and Sleep Medicine at Red Cross Maingau Hospital, Frankfurt am Main, Germany.
Walter LehmacherEmeritus, University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Andrea ZimmermannResearch & Development Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Juliette Brandes-SchrammResearch & Development Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Petra FunkResearch & Development Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Heinrich MatthysMedical Director Emeritus, Department of Pneumology, University Hospital Freiburg, Freiburg, Germany.
Wolfgang KaminChildren's Hospital, Evangelic Hospital Hamm GmbH, Hamm, Germany.
Dr Willmar Schwabe (Germany) · DEEvangelisches Krankenhaus Hamm · DERed Cross Hospital · GRUniversity Medical Center Freiburg · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cough is a leading symptom of viral acute respiratory infections such as acute bronchitis (AB) and the common cold (CC), which can be debilitating and may persist for several weeks. We investigated whether treatment with Methods: We performed a meta-analysis of randomized, placebo-controlled trials investigating the efficacy of EPs 7630 in AB or CC. Efficacy analyses included change from baseline in a cough intensity score, remission of cough, and disease-associated impairments of QoL. Results: Data of 2,195 participants from 11 trials (3 in children/adolescents with AB, 3 in adults with AB, 5 in adults with CC) were eligible. In children/adolescents with AB, 79.6% of participants treated with EPs 7630 and 41% treated with placebo showed a reduction in the intensity of cough by at least 50% of baseline values at day 7 [meta-analysis rate/risk ratio (RR), EPs 7630 / placebo: 1.86 (95% CI: 1.34; 2.95)], and 18.0% Conclusions: The results show that EPs 7630 reduces the burden and leads to earlier remission of cough. Advantages for EPs 7630 were also reflected in self-rated measures of disease-associated QoL. Of note, patients treated with the herbal product felt able to resume their usual daily activities sooner.

Indexed as

Acute bronchitisacute coughacute respiratory tract infectioncommon coldEPs 7630meta-analysisPelargoniumquality of life

Identifiers

PMID36051888
PMCPMC9425964
OpenAlexW4289549831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.